Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes

Journal of Molecular Recognition

Volumn 13, Issue 4, 2000, Pages 198-212

  Harris, Debra L ^a   King, Edward ^a   Ramsland, Paul A ^b   Edmundson, Allen B ^b  

^a UNIVERSITY OF UTAH   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

AL amyloidosis; Amyloid; Amyloidogenic light (L) chains; Bence Jones proteins; Collagen; Multiple myeloma

Indexed keywords

AMMONIUM SULFATE; BENCE JONES PROTEIN; BINDING KINETICS; COLLAGEN; CULTURE MEDIUM; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; FIBRIL; FIBROBLAST; HUMAN CELL CULTURE; HUMAN; LIGAND; MONOLAYER; MYELOMA CELL; URINE;

AMYLOID; AMYLOIDOSIS; ASPARTAME; BENCE JONES PROTEIN; BINDING SITES; CELL LINE; COLLAGEN; EXTRACELLULAR MATRIX; FIBROBLASTS; FOURIER ANALYSIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; MODELS, MOLECULAR; SKIN;

EID: 0033865983     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1352(200007/08)13:4<198::AID-JMR499>3.0.CO;2-D     Document Type: Article

References (65)

1. Aonuma S, Kohama Y, Makino T, Hattori K, Kawahara Y. 1984. Studies of heart. XXIV. Inhibitory effect of antiarrhythmic peptide (AAP) on experimental thromboses. Chem. Pharm. Bull. (Tokyo) 32: 219-227.
2. Bellotti V, Stoppini M, Mangione PP, Fornasieri A, Min L, Merlini G, Ferri G. 1996. Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications. Biochim. Biophys. Acta 1317: 161-167.
3. Brown C. 1966. A refinement of crystal structure of azobenzene. Acta. Crystallogr. 21: 146-152.
4. Brünger AT. 1992. X-PLOR Version 3.1 - a System for X-ray Crystallography and NMR, Yale Unversity Press, New Haven, CT.
5. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR. 1990. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chains deposition diseases and their relation to light chain amyloidosis; clinical features, immunopathology, and molecular analysis. Ann. Intern. Med. 112: 455-464.
6. Clyne DH, Pollak VE. 1981. Renal handling and pathophysiology of Bence-Jones proteins. Contrib. Nephrol. 24: 78-87.
7. Colon W, Kelly JW. 1992. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31: 8654-8660.
8. Connolly ML. 1983a. Analytical molecular surface calculation. J. Appl. Crystallogr. 16: 548-558.
9. Connolly ML. 1983b. Solvent-accessible surfaces of proteins and nucleic acids. Science 221: 709-713.
10. Coward RA, Mallick NP, Delamore IW. 1983. Tubular function in multiple myeloma. Clin. Nephrol. 24: 180-185.
11. Edmundson AB, Ely KR. 1986. Three-dimensional analyses of the binding of synthetic chemotactic and opioid peptides in the Mcg light chain dimer. In Synthetic Peptides as Antigens (Ciba Foundation Symposium 119) (Porter, R. & Whelan, J., eds.), pp. 107-129. Wiley, Chichester.
12. Edmundson AB, Manion CV. 1998. Treatment of osteoarthritis with aspartame. Clin. Pharmac. Ther 63: 580-593.
13. Edmundson AB, Ely KR, Girling RL, Abola EE, Schiffer M, Westholm FA. 1974a. Structure and binding properties of a λ-type Bence-Jones dimer. In Progress in Immunology II (Brent, L. & Holborow, J., eds.), Vol. 1, pp. 103-113. North-Holland, Amsterdam.
14. Edmundson AB, Ely KR, Girling RL, Abola EE, Schiffer M, Westholm FA, Fausch MD, Deutsch HF. 1974b. Binding of 2,4-dinitrophenyl compounds and other small molecules to a crystalline λ-type Bence-Jones dimer. Biochemistry 13: 3816-3827.
15. Edmundson AB, Ely KR, Abola EE, Schiffer M, Panagiotopoulos N. 1975. Rotational allomerism and divergent evolution of domains in immunoglobulin light chains. Biochemistry 14: 3953-3961.
16. Edmundson AB, Ely KR, Herron JN. 1984 A search for site-filling ligands in the Mcg Bence-Jones dimer: crystal binding studies of fluorescent compounds. Mol. Immunol. 21: 561-576.
17. Edmundson AB, Ely KR, Herron JN, Cheson BD. 1987. The binding of opioid peptides to the Mcg light chain dimer: flexible keys and adjustable locks. Mol. Immunol. 24: 915-935.
18. Edmundson AB, Ely KR, He XM, Herron JN. 1989a. Cocrystallization of an immunoglobulin light chain dimer with bis(dinitrophenyl) lysine: tandem binding of two ligands, one with and one without accompanying conformational changes in the protein. Mol. Immunol. 26: 207-220.
19. Edmundson AB, Herron JN, Ely KR, He X-M, Harris DL, Voss EW, Jr. 1989b. Synthetic site-directed ligands. Phil. Trans. R. Soc. Lond. B323: 495-509.
20. Edmundson AB, Harris DL, Fan Z-C, Guddat LW, Schley BT, Hanson BL, Tribbick G, Geysen HM. 1993. Principles and pitfalls in designing site-directed peptide ligands. Proteins Struct. Funct. Genet. 16: 246-267.
21. Edmundson AB, Guddat LW, Rosauer RA, Andersen KN, Shan L, Fan Z-C. 1995. Three-dimensional aspects of IgG structure and function. In The Antibodies (Zanetti, M. & Capra, J. D., eds.), Vol. 1, pp. 41-100. Harvard Academic, Luxembourg.
22. Ferrin TE, Huang CC, Jarvis LE, Langridge R. 1988. The MIDAS display system. J. Mol. Graph. 6: 13-27.
23. Gafni J, Merker H-J, Shibolet S, Sohar E, Heller H. 1966. On the origin of amyloid; study of an amyloid tumor in multiple myeloma. Ann. Intern. Med. 65: 1031-1044.
24. Gay S, Martin GR, Muller PK, Timpl R, Kuhn K. 1976. Simultaneous synthesis of types I and III collagen by fibroblasts in culture. Proc. Natl Acad. Sci. USA 73: 4037-4040.
25. Glenner GG. 1980. Amyloid deposits and amyloidosis; the β-fibrilloses. N. Engl. J. Med. 302: 1283-1292.
26. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL. 1971a. Creation of "amyloid" fibrils from Bence-Jones proteins in vitro. Science 174: 712-714.
27. Glenner GG, Terry W, Harada M, Isersky C, Page D. 1971b. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 172: 1150-1151.
28. Hashimoto K, Gross BG, Lever WF. 1965. Lichen amyloidosis; histochemical and electron microscopic studies. J. Invest. Derm. 45: 204-219.
29. Helms LR, Wetzel R. 1996. Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis. J. Mol. Biol. 257: 77-86.
30. Hendrickson WA. 1985. Stereochemically restrained refinement of macromolecular structures. Meth. Enzymol. 115: 252-270.
31. Hill GS, Morel-Maroger L, Mery JP, Brouet JC, Mignon F. 1983. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities Am. J. Kidney Dis. 2: 423-438.
32. Huang Z-Q, Kirk KA, Connelly KG, Sanders PW. 1993. Bence-Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J. Clin. Invest. 92: 2975-2383.
33. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. 1994. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl Acad. Sci. USA 91: 5446-5450.
34. Kelly JW. 1996. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct Biol. 6: 11-17.
35. Kisilevsky R. 1983. Amyloidosis: a familiar problem in the light of current pathogenetic developments. Lab. Invest. 49: 381-390.
36. Koss MN, Pirani CL, Osserman EF. 1976. Experimental Bence-Jones cast nephropathy. Lab. Invest. 4: 579-591.
37. Layman DL, McGoodwin EB, Martin GR. 1971. The nature of the collagen synthesized by cultured human fibroblasts. Proc. Natl Acad. Sci. USA 68: 454-458.
38. Linke RP, Zucker-Franklin D, Franklin EC. 1973. Morphologic, chemical, and immunologic studies of amyloid-like fibrils formed from Bence-Jones proteins by proteolysis. J. Immunol. 111: 10-23.
39. Mostad A, Romming C. 1971. Refinement of crystal-structure of cisazobenzene. Acta Chem. Scand. 25: 3561.
40. Nagai Y, Sakakibara S, Noda H, Akabori S. 1960. Hydrolysis of synthetic peptides by collagenase. Biochim. Biophys. Acta 37: 567-569.
41. Picot D, Loll PJ, Garavito RM. 1994. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367: 243-249.
42. Pokkuluri PR, Solomon A, Weiss DT, Stevens FJ, Schiffer M. 1999. Tertiary structure of human lambda 6 light chains. Amyloid 6: 165-171.
43. Puchtler H, Sweat F, Levine M. 1962. On the binding of Congo Red by amyloid. J. Histochem. Cytochem. 10: 355-364.
44. Raffen R, Dieckman LJ, Szpunar M, Wunschl C, Pokkuluri PR, Dave P, Wilkins Stevens P, Cai X, Schiffer M, Stevens FJ. 1999. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci. 8: 509-517.
45. Roussel A, Cambillau C. 1989. TURBO-FRODO molecular graphics program. In Silicon Graphics Geometry Partner Directory (Fall 1989) (Graphics, S., ed,), pp. 77-78. Silicon Graphics, Mountain View, CA.
46. Sakakibara S, Kishida Y, Kikuchi Y, Sakai R, Kakiuchi K. 1968. Synthesis of poly-(L-prolyl-L-prolyglycl) of molecular weights definite. Bull. Chem. Soc. Jpn 41: 1273.
47. Sakakibara S, Inouye K, Shudo K, Kishida Y, Kobayashi Y, Prockop D. 1973. Synthesis of (pro-hyp-gly)n of defined molecular weights. Evidence for the stabilization of collagen triple helix by hydroxypyroline. Biochim. Biophys. Acta 303: 198-202.
48. Shirahama T, Benson MD, Cohen AS, Tanaka A. 1973. Fibrillar assemblage of variable segments of immunoglobulin light chains: an electron microscopic study. J. Immunol. 110: 21-30.
49. Solomon A. 1982. Bence-Jones proteins: malignant or benign? N. Engl. J. Med. 306: 605-607.
50. Solomon A. 1985. Light chains of human immunoglobulins. Meth. Enzymol. 116: 101-121.
51. Solomon A, McLaughlin CL. 1969. Bence-Jones proteins and light chains of immunoglobulins. I. Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves. J. Biol. Chem. 244: 3393-3404.
52. Solomon A, Weiss DT. 1995. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid: Int. J. Exp. Clin. Invest. 2: 269-279.
53. λVI subgroup of human light chains with amyloidosis AL(λ). J. Clin. Invest. 70: 453-460.
54. Solomon A, Weiss DT, Kattine AA. 1991. Nephrotoxic potential of Bence-Jones proteins. N. Engl. J. Med. 324: 1845-1851.
55. Solomon A, Weiss DT, Pepys MB. 1992a. Induction in mice of human light-chain-associated amyloidosis. Am. J. Pathol. 140: 629-637.
56. Solomon A, Weiss DT, Williams TK. 1992b. Experimental model of human light-chain-associated disease. Curr. Top. Microbiol. Immunol. 182: 261-267.
57. Solomon A, Weiss DT, Murphy CL, Hrncic R, Wall JS, Schell M. 1998. Light chain-associated amyloid deposits comprised of a novel kappa constant domain. Proc. Natl Acad. Sci. USA 95: 9547-9551.
58. Solomon A, Weiss DT, Schell M, Hrncic R, Murphy CL, Wall J, McGavin MD, Pan HJ, Kabalka GW, Paulus MJ. 1999. Transgenic mouse model of AA amyloidosis. Am. J. Pathol. 154: 1267-1272.
59. Stevens PW, Raffen R, Hanson DK, Deng Y-L, Berrios-Hammond M, Westholm FA, Murphy C, Eulitz M, Wetzel R, Solomon A, Schiffer M, Stevens FJ. 1995. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci. 4: 421-432.
60. Stone MJ. 1990. Amyloidosis: a final common pathway for protein deposition in tissues. Blood 75: 531-545.
61. Strauch L, Vencelj H. 1967. Collangenases in mammalian cells. Hoppe-Seyler's Z. Physiol. Chem. 348: 465-468.
62. Tan M, Epstein W. 1972. Polymer formation during the degradation of human light chain and Bence-Jones proteins by an extract of the lysosomal fraction of normal human kidney. Immunochemistry 9: 9-16.
63. Wall J, Murphy CL, Solomon A. 1999a. In vitro immunoglobulin light chain fibrillogenesis. Meth. Enzymol. 309: 204-217.
64. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. 1999b. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38: 14101-14108.
65. Wünsch EK, Heidrich JG. 1963. Binding studies of a series of peptides for use in protein chemistry: a model. Hoppe-Seyler's Z. Physiol. Chem. 333: 149-162.